I-MAB (IMAB) Debt-to-Asset : 0.05 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Debt-to-Asset?

I-MAB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $7.26 Mil. I-MAB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $11.49 Mil. I-MAB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $365.95 Mil. I-MAB's debt to asset for the quarter that ended in Dec. 2023 was 0.05.

I-MAB Debt-to-Asset Historical Data

The historical data trend for I-MAB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Debt-to-Asset Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.08

0.02

0.05

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial								0.02	0.02	0.02	0.02	0.05

Competitive Comparison of I-MAB's Debt-to-Asset

For the Biotechnology subindustry, I-MAB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

I-MAB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where I-MAB's Debt-to-Asset falls into.

I-MAB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

I-MAB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.263	+	11.486)	/	365.952
	=	0.05

I-MAB's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.263	+	11.486)	/	365.952
	=	0.05

I-MAB (NAS:IMAB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

I-MAB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of I-MAB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.